FDA Moves To Shut Down Two Stem Cell Clinics as Part of Its Oversight of Regenerative Medicine Products

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

FDA Moves To Shut Down Two Stem Cell Clinics as Part of Its Oversight of Regenerative Medicine Products

Companies Dispute FDA’s Jurisdiction Over Stem Cell Therapy, Say They Are Defending ‘Medical Freedom’

Dennis Tosh

May 17, 2018 at 12:43 PM EST

The Department of Justice (DOJ), acting on behalf of the FDA, filed complaints May 9 in two federal district courts seeking permanent injunctions to prevent two stem cell clinics from marketing unapproved stem cell products and from manufacturing the products under conditions that violate current good manufacturing practice (cGMP) requirements. Treatments at one of clinics al... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

FDA Moves To Shut Down Two Stem Cell Clinics as Part of Its Oversight of Regenerative Medicine Products

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

FDA Moves To Shut Down Two Stem Cell Clinics as Part of Its Oversight of Regenerative Medicine Products

My Research Folders

Related Articles

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT